sources: 15392
Data license: CC-BY
This data as json
id | name | description | createdAt | updatedAt | datasetId | additionalInfo | link | dataPublishedBy |
---|---|---|---|---|---|---|---|---|
15392 | Estimated antiretroviral therapy coverage among people living with HIV (%) | { "link": "http://apps.who.int/gho/data/node.home", "retrievedDate": "23-March-18", "additionalInfo": "Indicator name\nEstimated antiretroviral therapy coverage among people living with HIV (%)\n\nName abbreviated\nART coverage among people living with HIV (%)\n\nData Type Representation\nPercent\n\nTopic\nHealth service coverage\n\nISO Health Indicators Framework\n\n \n\nRationale\nAntiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with\u00a0 HIV infection. As the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Over recent years WHO has issued various updates in the ARV guidelines. Under the 2013 WHO consolidated guidelines, roughly 85% people living with HIV would be eligible for treatment in 2013. For reasons of comparibility across countries and over time in the context of changing recommendations, this indicator relates to the number of people receiving ART as of proportion of the overall estimated number of people living with HIV.\u00a0 The ranges around the levels of people living with HIV who received ART are based on the uncertainty bounds around the estimates of people living with HIV.\n\nDefinition\nPercentage of people living with HIV currently receiving ART among the estimated number of adults and children living with HIV. Numerator: Number of adults and children who are currently receiving ART at the end of the reporting period. Denominator: Estimated number of adults and children living with HIV. \n\t\n\nAssociated terms\nAntiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO standards). ARV regimen prescribed for post exposure prophylaxis are excluded.\n\nAssociated terms\nHuman Immunodeficiency Virus (HIV) : A\u00a0virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body\u2019s ability to fight off infection and disease, which can ultimately lead to death.\n\nPreferred data sources\nFacility reporting system\n\nOther possible data sources\nSentinel surveillance sites\n\nOther possible data sources\nPopulation-based surveys\n\nMethod of measurement\nNumerator: The numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Data can be collected from facility-based ART registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving ART in the private sector and public sector should be included in the numerator where data are available.\n\tDenominator: The denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) ART. This estimation must take into consideration a variety of factors, including, but not limited to, the current number of people with HIV, the current number of patients on ART and the natural history of HIV from infection to enrolment on ART. A standard modelling HIV estimation method, such as in the Spectrum model, is recommended.\n\t\n\nMethod of estimation\nModelling, using multiple inputs specific to the HIV epidemic context, is typically used to obtain an estimate of the number of people living with HIV and national programme records are used to determine the number receiving treatment. UNAIDS supports most countries to produce estimates of the number of people living with HIV annually using Spectrum.\u00a0\n\nM&E Framework\nOutcome\n\nMethod of estimation of global and regional aggregates\nRegional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country\u2019s share of the total number of people living with HIV. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no estimates have been established for most high-income countries. Aggregated coverage percentages are based solely on low- and middle-income countries.\n\nDisaggregation\nAge: 1. Minimum for paper-based (routine): less than 15, 15+; 2. Annual data extraction of disaggregated data if not reported routinely: less than 5, 5\u20139, 10\u201314, 15\u201319, 20\u201324, 25\u201349, 50+; 3. Electronic system: 5-year age groups\n\nDisaggregation\nSex\n\nDisaggregation\nGeographic location\n\nDisaggregation\nKey populations (men who have sex with men, sex workers, people who inject drugs, transgender people, prisoners)\n\t\n\nDisaggregation\nProvider type (public/private)\n\nDisaggregation\nRegimen type (e.g. first line, second line)\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\nAnnual\n\nLimitations\nEstimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.\n\tTo analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of people living with HIV. Specialized software is used to generate uncertainty ranges around estimates. Depending on the quality of surveillance data, the ranges for some countries can be large.\n\t\n\nLinks\nConsolidated Strategic Information Guidelines for HIV in the Health Sector. Geneva: World Health Organization; 2015 (accessed 10 June 2015).\n\t\n\nLinks\nFramework of actions for the follow-up to the Programme of Action of the International Conference on Population and Development beyond 2014. Report of the Secretary-General. New York (NY): United Nations; 2014 (accessed 19 August 2014).\n\t\n\nLinks\nGlobal AIDS Monitoring 2017 Indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS(UNAIDS/WHO/UNICEF), 2016.\n\nLinks\nIndicators for monitoring the Millennium Development Goals: definitions, rationale, concepts and sources. New York (NY): United Nations; 2012 (accessed 29 March 2015).\n\t\n\nLinks\nNext generation indicators reference guide: planning and reporting. Version 1.2. Washington (DC): The President\u2019s Emergency Plan for AIDS Relief; 2013 (accessed 29 March 2014).\n\t\n\nLinks\nSpectrum software. Glastonbury (CT): Avenir Health. (accessed 29 March 2015).\n\t\n\nComments\n\u00a0\n\nContact Person\n\n \n\n", "dataPublishedBy": "World Health Organization Global Health Observatory (GHO)", "dataPublisherSource": null } |
2018-03-23 12:44:42 | 2018-03-23 12:44:42 | 2694 | Indicator name Estimated antiretroviral therapy coverage among people living with HIV (%) Name abbreviated ART coverage among people living with HIV (%) Data Type Representation Percent Topic Health service coverage ISO Health Indicators Framework Rationale Antiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with HIV infection. As the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Over recent years WHO has issued various updates in the ARV guidelines. Under the 2013 WHO consolidated guidelines, roughly 85% people living with HIV would be eligible for treatment in 2013. For reasons of comparibility across countries and over time in the context of changing recommendations, this indicator relates to the number of people receiving ART as of proportion of the overall estimated number of people living with HIV. The ranges around the levels of people living with HIV who received ART are based on the uncertainty bounds around the estimates of people living with HIV. Definition Percentage of people living with HIV currently receiving ART among the estimated number of adults and children living with HIV. Numerator: Number of adults and children who are currently receiving ART at the end of the reporting period. Denominator: Estimated number of adults and children living with HIV. Associated terms Antiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO standards). ARV regimen prescribed for post exposure prophylaxis are excluded. Associated terms Human Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death. Preferred data sources Facility reporting system Other possible data sources Sentinel surveillance sites Other possible data sources Population-based surveys Method of measurement Numerator: The numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Data can be collected from facility-based ART registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving ART in the private sector and public sector should be included in the numerator where data are available. Denominator: The denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) ART. This estimation must take into consideration a variety of factors, including, but not limited to, the current number of people with HIV, the current number of patients on ART and the natural history of HIV from infection to enrolment on ART. A standard modelling HIV estimation method, such as in the Spectrum model, is recommended. Method of estimation Modelling, using multiple inputs specific to the HIV epidemic context, is typically used to obtain an estimate of the number of people living with HIV and national programme records are used to determine the number receiving treatment. UNAIDS supports most countries to produce estimates of the number of people living with HIV annually using Spectrum. M&E Framework Outcome Method of estimation of global and regional aggregates Regional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people living with HIV. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no estimates have been established for most high-income countries. Aggregated coverage percentages are based solely on low- and middle-income countries. Disaggregation Age: 1. Minimum for paper-based (routine): less than 15, 15+; 2. Annual data extraction of disaggregated data if not reported routinely: less than 5, 5–9, 10–14, 15–19, 20–24, 25–49, 50+; 3. Electronic system: 5-year age groups Disaggregation Sex Disaggregation Geographic location Disaggregation Key populations (men who have sex with men, sex workers, people who inject drugs, transgender people, prisoners) Disaggregation Provider type (public/private) Disaggregation Regimen type (e.g. first line, second line) Unit of Measure Unit Multiplier Expected frequency of data dissemination Annual Expected frequency of data collection Annual Limitations Estimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die. To analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of people living with HIV. Specialized software is used to generate uncertainty ranges around estimates. Depending on the quality of surveillance data, the ranges for some countries can be large. Links Consolidated Strategic Information Guidelines for HIV in the Health Sector. Geneva: World Health Organization; 2015 (accessed 10 June 2015). Links Framework of actions for the follow-up to the Programme of Action of the International Conference on Population and Development beyond 2014. Report of the Secretary-General. New York (NY): United Nations; 2014 (accessed 19 August 2014). Links Global AIDS Monitoring 2017 Indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS(UNAIDS/WHO/UNICEF), 2016. Links Indicators for monitoring the Millennium Development Goals: definitions, rationale, concepts and sources. New York (NY): United Nations; 2012 (accessed 29 March 2015). Links Next generation indicators reference guide: planning and reporting. Version 1.2. Washington (DC): The President’s Emergency Plan for AIDS Relief; 2013 (accessed 29 March 2014). Links Spectrum software. Glastonbury (CT): Avenir Health. (accessed 29 March 2015). Comments Contact Person | http://apps.who.int/gho/data/node.home | World Health Organization Global Health Observatory (GHO) |
Links from other tables
- 1 row from sourceId in variables